Castle Creek Pharmaceutical Holdings Completes Acquisition of Fibrocell Science
- Acquisition complements and expands Castle Creek clinical development pipeline to include gene therapy platform - - Strategic acquisition to result in advancement of multiple late-stage investigational therapies for epidermolysis bullosa and other rare conditions – Exton, PA., December 16, 2019 -- Castle Creek Pharmaceutical Holdings, Inc. (“CCP Holdings”), a privately held company focused